Non-Small Cell Lung Cancer (NSCLC)

Osimertinib Plus Platinum–Pemetrexed Improves Overall Survival in EGFR-Mutated Advanced NSCLC (FLAURA2)

Final results from the phase III FLAURA2 trial demonstrate that adding platinum–pemetrexed chemotherapy to first-line osimertinib significantly improves overall survival (OS) in patients with EGFR-mutated...

Latest Posts

FDA Grants Approval for Subcutaneous Amibantamab (Rybrevant Faspro) in EGFR-Mutated NSCLC

The FDA has approved subcutaneous amivantamab (Rybrevant Faspro) for adult patients with advanced or metastatic...

EMPOWER-Lung 1: Cemiplimab Shows Sustained 5-Year Survival Benefit in Advanced NSCLC

Five-year OS probability was 29.0% for cemiplimab and 15.0% for chemotherapy in advanced NSCLC patients...

Zipalertinib Demonstrates Activity in EGFR-Mutant NSCLC: Updated REZILIENT Trial Results from IASLC 2025

Zipalertinib demonstrated 27.4% response rate in EGFR ex20ins NSCLC patients post-amivantamab with 8.5-month duration of...

ANKTIVA® Reverses Lymphopenia and Extends Survival in Checkpoint Inhibitor-Resistant NSCLC: Phase 2 Results Support Paradigm Shift

ANKTIVA reverses lymphopenia in 80% of checkpoint-resistant NSCLC patients, extending survival to 21.1 months in...

FLAURA2 Final Analysis: Osimertinib Plus Chemotherapy Sets New Survival Standard in EGFR-Mutated Lung Cancer

Tagrisso plus chemo shows 47.5 months median OS vs 37.6 months monotherapy in EGFR+ lung...

Overcoming Immune Checkpoint Inhibitor Resistance in NSCLC: A Review of Emerging Therapeutic Strategies

60-85% of NSCLC patients develop secondary resistance to ICIs, creating critical unmet need requiring novel...

Histology Drives Lung Cancer Screening Effectiveness: Major Analysis of NELSON and NLST Trials

Screening effectiveness varies by histology, with adenocarcinoma showing 17.8-23.0% mortality reduction across trials.

FDA Approves Zongertinib as First Oral HER2-Targeted Therapy for NSCLC; Added to NCCN Guidelines

Zongertinib becomes first oral HER2-targeted therapy for NSCLC, achieving 75% response rate in previously treated...

FDA Grants Breakthrough Therapy Designation to Izalontamab Brengitecan for Treatment-Resistant EGFR-Mutated NSCLC

FDA grants Breakthrough Therapy Designation to izalontamab brengitecan for previously treated EGFR-mutated NSCLC patients.

Plasma-Guided Adaptive Treatment for First-Line NSCLC Therapy

ctDNA kinetics guide treatment intensification in NSCLC, achieving 11.0-month median PFS with less platinum exposure...

Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non-Small Cell Lung Cancer Patients

"Steroids were the biggest predictor of why certain immunotherapies may not be effective" - Dr....

CheckMate 77T: Perioperative Nivolumab Shows Long-Term EFS and ‘Favorable’ OS Trend in Resectable NSCLC

Perioperative nivolumab continued to demonstrate event-free survival benefits versus placebo in patients with resectable NSCLC.

FDA Greenlights Oral Therapy for NSCLC With EGFR Exon20 Insertion Mutations

FDA approves sunvozertinib for NSCLC with EGFR exon20 insertion mutations - first oral targeted therapy...

Lung Cancer Insight Center

Small Cell Lung Cancer (SCLC)

About
Contact
Privacy Policy
Terms of Use

About
Contact
Privacy Policy
Terms of Use

732-455-2192
contact@oncologynexus.com

Facebook-f Twitter Google-plus-g Pinterest